Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia (Q30887348)

27 June 2017

1 reference

title

Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia (English)

1 reference

27 June 2017

1 reference

P C Gotzsche

1 reference

27 June 2017

H K Johansen

1 reference

27 June 2017

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

published in

1 reference

27 June 2017

1 reference

27 June 2017

page(s)

CD000969

1 reference

A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Use of amphotericin B colloidal dispersion in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Conventional vs. liposomal amphotericin B in immunosuppressed children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Liposomal amphotericin B for fever and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Routine versus selective antifungal administration for control of fungal infections in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Must we really fear toxicity of conventional amphotericin B in oncological patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Antifungal therapy in 'bone marrow failure'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

Do the new lipid formulations of amphotericin B really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000969

10.1002/14651858.CD000969

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference